PMID- 10082337
OWN - NLM
STAT- MEDLINE
DCOM- 19990615
LR  - 20190909
IS  - 0887-8994 (Print)
IS  - 0887-8994 (Linking)
VI  - 20
IP  - 2
DP  - 1999 Feb
TI  - Vigabatrin in the treatment of infantile spasms.
PG  - 106-10
AB  - Infantile spasms (IS) have been conventionally treated with adrenocorticotropic 
      hormone (ACTH), which is often associated with significant side effects. This 
      study assessed the efficacy of vigabatrin (VGB) as an alternative in the 
      treatment of IS and compared the efficacy of VGB in symptomatic vs cryptogenic 
      patients. The study retrospectively reviewed 25 infants with IS (19 symptomatic, 
      six cryptogenic) who were treated with VGB. Of the symptomatic group, 13 (68.4%) 
      of 19 had clinical improvement, and 15 (78.9%) had electroencephalographic 
      improvement. Three (50%) of six in the cryptogenic group had clinical 
      improvement, and two (33%) had electroencephalographic improvement. Overall, 
      three patients demonstrated clinical spasm control but electroencephalographic 
      deterioration or persistence of hypsarrhythmia coupled with further cognitive 
      decline. Four of the six partial clinical responders had deterioration of spasms 
      with additional VGB dosage increases. VGB is comparable with ACTH in 
      effectiveness for treatment of symptomatic IS. Higher doses of VGB may sometimes 
      cause deterioration rather than further improvement, and therefore an optimum 
      dosage of VGB needs to be titrated for every patient. Persistent 
      electroencephalographic abnormalities and even electroencephalographic 
      deterioration despite clinical control have been observed with VGB treatment; 
      electroencephalographic monitoring during VGB treatment is recommended.
FAU - Koo, B
AU  - Koo B
AD  - Department of Neurology, Children's Hospital of Michigan, Wayne State University, 
      Detroit 48201, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Neurol
JT  - Pediatric neurology
JID - 8508183
RN  - 0 (Anticonvulsants)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - GR120KRT6K (Vigabatrin)
SB  - IM
MH  - Adrenocorticotropic Hormone/therapeutic use
MH  - Anticonvulsants/*therapeutic use
MH  - Drug Resistance
MH  - Electroencephalography
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Retrospective Studies
MH  - Spasms, Infantile/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vigabatrin
MH  - gamma-Aminobutyric Acid/*analogs & derivatives/therapeutic use
EDAT- 1999/03/19 00:00
MHDA- 1999/03/19 00:01
CRDT- 1999/03/19 00:00
PHST- 1999/03/19 00:00 [pubmed]
PHST- 1999/03/19 00:01 [medline]
PHST- 1999/03/19 00:00 [entrez]
AID - S0887-8994(98)00116-7 [pii]
AID - 10.1016/s0887-8994(98)00116-7 [doi]
PST - ppublish
SO  - Pediatr Neurol. 1999 Feb;20(2):106-10. doi: 10.1016/s0887-8994(98)00116-7.